---
title: "20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74) M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281252205.md"
description: "20/20 Biolabs reported fiscal-year revenue of $2.045 million, a 16.7% increase from the previous year, but recorded a net loss of $(3.739) million. Gross profit improved to $0.605 million with a 29.56% margin. The growth was driven by higher OneTest sales and a shift to a premium test mix. The company launched a new product, OneTest for Longevity, and began multi-cancer screenings for veterans, indicating market expansion. Cost efficiency initiatives led to improved gross margins and reduced operating expenses."
datetime: "2026-03-31T21:35:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281252205.md)
  - [en](https://longbridge.com/en/news/281252205.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281252205.md)
---

# 20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74) M

20/20 Biolabs reported fiscal-year revenue of $2.045 million, a 16.7% increase versus the prior year, driven by higher OneTest and CLIAx sales, and recorded a net loss of $(3.739) million (net loss per share not disclosed). Gross profit improved to $0.605 million with a 29.56% margin, while the company reported an operating loss of $(3.331) million as operating expenses remained elevated relative to revenues.

**Financial Highlights**

-   **Revenue:** $2.045 million, up 16.7% year‑over‑year.
-   **Gross Profit:** $0.605 million; gross margin 29.56% (vs. 20.56% prior year).
-   **Operating Loss:** $(3.331) million; operating expenses were 192.43% of revenues.
-   **Net Loss:** $(3.739) million, improved 32.7% versus prior year.
-   **Net Loss Per Share:** Not stated in the provided filing excerpts.

**Business Highlights**

-   **Revenue Drivers:** Growth was driven by higher OneTest sales and a shift to a premium test mix, including price increases that improved average revenue per unit.
-   **Product Mix:** Increased sales of Premium OneTest (about 35% more sold) contributed to improved product margins.
-   **New Product Launch:** Launched OneTest for Longevity in February 2026.
-   **Market Expansion:** Began multi-cancer screenings for veterans, indicating expansion of clinical service offerings.
-   **Operational Capacity:** All testing is performed in the company’s CLIA laboratory in Gaithersburg; the company operates a CLIAx shared lab model for international startups.
-   **Cost and Efficiency Initiatives:** Gross margin improvement and reductions in SG&A and R&D were achieved through in‑house marketing and prioritization of R&D efforts.

Original SEC Filing: 20/20 Biolabs, Inc. \[ AIDX \] - 10-K - Mar. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [AIDX.US](https://longbridge.com/en/quote/AIDX.US.md)

## Related News & Research

- [20/20 BioLabs Q1 Revenue Slips; Eyes Q2 Growth From Maryland Firefighter Cancer Screening Program](https://longbridge.com/en/news/287177470.md)
- [3 Vanguard ETFs with 20%+ Upside That Could Crush VOO in 2026](https://longbridge.com/en/news/287026519.md)
- [Here's How Much $1000 Invested In Heico 20 Years Ago Would Be Worth Today](https://longbridge.com/en/news/287144320.md)
- [If You Invested $100 In AutoZone Stock 20 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/287099466.md)
- [Why Are Stock Market Futures Down Today, 5/20/26?](https://longbridge.com/en/news/287128012.md)